Arbutus Biopharma (ABUS) Change in Receivables (2013 - 2026)

Arbutus Biopharma has disclosed Change in Receivables across 14 years of filings, most recently posting $178.7 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at $178.7 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $177.4 million (up 65591.11% YoY), and the FY2025 annual result was -$1.4 million, down 317.22% from the prior year.
• Change in Receivables came in at $178.7 million for Q1 2026 at Arbutus Biopharma, up from $129000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $178.7 million in Q1 2026 to a low of -$1.4 million in Q2 2025.
• The 5-year median for Change in Receivables is -$85000.0 (2023), against an average of $11.2 million.
• Across the five-year window, Change in Receivables jumped 1890.91% in 2022 and plunged 644.0% in 2024, its largest moves.
• Arbutus Biopharma's Change in Receivables stood at -$483000.0 in 2022, then rose by 18.22% to -$395000.0 in 2023, then surged by 302.78% to $801000.0 in 2024, then plunged by 83.9% to $129000.0 in 2025, then jumped by 138458.91% to $178.7 million in 2026.
• The last three Change in Receivables figures came in at $178.7 million (Q1 2026), $129000.0 (Q4 2025), and -$120000.0 (Q3 2025), per Business Quant data.